To date, the impact of protein kinases on AR function has been extensively studied (reviewed in [10]), with modulation of AR activity via the inhibition of upstream kinases including Aurora A [11], CDK1 [12] and MAPK [13], representing proven examples that AR co-activator inhibition may represent a viable therapeutic approach in PC and CRPC. Here, AR is linked to pachyonychia congenita.